logo

For the Inventor, By the Inventor

Fremont, CA, United States of America

Asterias Biotherapeutics, Inc.


USPTO Granted Patents = 23

% Expired Patents = 47.8



Forward Citations = 41

Loading Chart...
Loading Chart...

32 inventors (with patents filed for the assignee):

goldMedal Ramkumar Mandalam (7 out of 14 patents)

silverMedal Melissa K Carpenter (7 out of 32 patents)

bronzeMedal Jane S Lebkowski (5 out of 20 patents)

4.  Joseph D Gold (5 out of 24 patents)

5.  Nathan C Manley (4 out of 5 patents)

6.  Yue Zhou (4 out of 28 patents)

7.  Christopher Bankole Shogbon (4 out of 12 patents)

8.  Ralph Brandenberger (4 out of 9 patents)

9.  Yan Li (3 out of 32 patents)

10.  Isabelle Nadeau-Demers (3 out of 3 patents)

11.  Chunhui Xu (3 out of 17 patents)

12.  Erik Michael Whiteley (3 out of 4 patents)

13.  Edward D Wirth, Iii (2 out of 2 patents)

14.  R Scott Thies (2 out of 9 patents)

15.  Uzma Shoukat-Mumtaz (2 out of 3 patents)


23 patents:

1. 12716054 - Oligodendrocyte progenitor cell compositions (2026-08-25),
2. 12441983 - Suspension culture of human embryonic stem cells (2025-10-14),
3. 11920155 - Oligodendrocyte progenitor cell compositions (2024-03-05),
4. 11603518 - Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells (2023-03-14),
5. 11123374 - Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury (2021-09-21),
6. 10676714 - Suspension culture of human embryonic stem cells (2020-06-09),
7. 10351821 - Neural cell populations from primate pluripotent stem cells (2019-07-16),
8. 10344262 - Differentiation of primate pluripotent stem cells to hematopoietic lineage cells (2019-07-09),
9. 10286009 - Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury (2019-05-14),
10. 10221390 - Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells (2019-03-05),
11. 10059939 - Screening methods for human embryonic stem cells (2018-08-28),
12. 9803174 - Neural progenitor cell populations (2017-10-31),
13. 9790466 - Neural cell populations from primate pluripotent stem cells (2017-10-17),
14. 9745550 - Synthetic surfaces for culturing stem cell derived cardiomyocytes (2017-08-29),
15. 9587223 - Protocols for making hepatocytes from embryonic stem cells (2017-03-07),
Company Overview
Asterias Biotherapeutics, Inc. is a biotechnology company based in Fremont, California, specializing in the development of innovative cell therapies. The organization focuses on harnessing the potential of stem cells to create treatments for various medical conditions, particularly in the fields of regenerative medicine and immunotherapy. Asterias is dedicated to advancing its research in cellular therapies, aiming to address unmet medical needs and improve patient outcomes through cutting-edge scientific advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Asterias Biotherapeutics, Inc. USPTO Patent Assignee Logo
23 Patents

#95 in Fremont, CA

#3,421 in California

#14,438 in US

#27,714 in the World

Fremont, CA (US)
Fremont, CA, United States of America

Asterias Biotherapeutics, Inc.

Forward Citations = 41

32 inventors:

goldMedal Ramkumar Mandalam (7 out of 14 patents)

silverMedal Melissa K Carpenter (7 out of 32 patents)

bronzeMedal Jane S Lebkowski (5 out of 20 patents)

4.  Joseph D Gold (5 out of 24 patents)

5.  Nathan C Manley (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Asterias Biotherapeutics, Inc.. Retrieved from https://idiyas.com/company/asterias-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…